GLP-1 alternatives for weight loss: what the evidence actually shows

What did @authentic_abi actually say?

She said she takes sertraline (100mg) for anxiety and depression, added something called "TESL Fenzene" (likely a compounded or branded tryptophan/5-HTP or fenethylline-adjacent product marketed as an SSRI), experienced elevated heart rate and blood pressure, suspected serotonin syndrome by her own admission, stopped it, and is now reintroducing it at a slow titration schedule. Her words: "I accidentally gave myself serotonin syndrome, but I enjoyed the medication... I'm willing to risk it again."

She also frames this as evidence of how powerful the product is and encourages viewers to "customize your treatment plan" to make it "work for you in the way that you want it to work."

She does credit her provider, Andrea Meisinger, ARNP, FNP-BC, and mentions following provider instructions. That part matters. But the overall framing treats a dangerous drug interaction as a selling point.

Does the science back this up?

No. Combining two serotonergic agents significantly raises the risk of serotonin syndrome, and surviving a mild case is not a green light to retry the combination. The science on this is not ambiguous.

Serotonin syndrome ranges from mild (tremor, tachycardia, diaphoresis) to life-threatening (hyperthermia, seizures, rhabdomyolysis). Boyer and Shannon (2005, NEJM) described the Hunter Criteria, which remain the standard diagnostic framework. Key triggers include combinations of SSRIs with other serotonergic compounds, which is exactly what she describes.

The elevated heart rate and blood pressure she mentions are classic autonomic features of serotonin toxicity. These are not signs that a medication is "powerful" in a good way. They are signs the serotonergic system is being overstimulated. Reintroducing the same combination, even slowly, without confirmed clinical supervision carries real risk. A slow titration reduces the rate of accumulation but does not eliminate the pharmacodynamic interaction driving the problem.

What did they get wrong (or right)?

She got the basic pharmacology wrong by treating serotonin syndrome as a tolerable side effect rather than a warning to reassess the combination entirely. The framing that her heart "didn't agree" but she "loved how she was feeling" inverts the medical priority. Subjective wellbeing does not override objective cardiovascular signals.

She also implies the product is an SSRI, saying "this is also an SSRI" without identifying the active ingredient clearly. If "TESL Fenzene" contains tryptophan, 5-HTP, St. John's Wort, or any serotonin precursor or reuptake inhibitor, the interaction risk with sertraline is well-documented.Birmes et al. (2003, Intensive Care Medicine) found serotonin syndrome cases frequently involved patients who did not recognize supplement-drug interactions as dangerous.

What she got right: she credits her provider, she acknowledges she backed off when her body reacted, and she says to follow provider guidance. That is not nothing. But it is buried under messaging that normalizes re-challenging a drug combination that already caused a medical event.

What should you actually know?

Serotonin syndrome is not a badge of medication efficacy. If a combination of serotonergic agents raised your heart rate, elevated your blood pressure, and your provider had you stop, that is not a story about how powerful a supplement is. That is a story about a drug interaction that worked exactly as the pharmacology predicts.

"Customizing your treatment plan" is legitimate in many contexts. In this one, it describes reintroducing a combination that already triggered an adverse event, which requires careful clinical oversight, not a self-designed every-three-days schedule shared on TikTok.

Anyone taking an SSRI, SNRI, MAOI, tricyclic antidepressant, tramadol, triptans, or lithium should flag any new serotonergic supplement or compound to their prescriber before starting. The FDA's Drug Safety Communication on serotonin syndrome (2016) specifically calls out the risk of combining these drug classes. If you experience rapid heart rate, restlessness, muscle twitching, or sweating after starting something new alongside an existing serotonergic drug, that is an emergency room situation, not a titration problem.

• Serotonin syndrome can progress from mild to severe within hours.
• The Hunter Criteria (Boyer and Shannon, 2005) require clonus, agitation, diaphoresis, tremor, or hyperreflexia, not just elevated vitals, but elevated vitals alone warrant stopping and reassessing.
• Slow reintroduction does not resolve a pharmacodynamic interaction. It only slows the buildup.